Affimed slips as finance chief and science chief depart
by
Contributor since / Followers
Contributor since / Followers
12 months ago
pcess609
- Affimed N.V. (NASDAQ:AFMD) shares lost ~13% on Thursday after the German biotech announced that its Chief Financial Officer, Angus Smith, and Chief Scientific Officer, Arndt Schottelius, will both resign from the company.
- Smith, who served Affirmed (AFMD) as CFO for three and a half years, will resign with effect from December 31, 2023, to take up a new CFO role at a Boston-based biotech, the company said in a regulatory filing.
- Dr. Schottelius has also communicated his decision to resign by the end of May 2024 to become the CEO of a European biotech, Affirmed (AFMD) said, adding that he will help the company find a replacement.
- While the company has started an executive search to find a permanent CFO, it has appointed Harry Welten, a veteran financial and biotechnology executive, to lead the finance function on an interim basis starting December 31, 2023.
- Welten, a former CFO of publicly traded biotech companies such as Horizon Pharma AG, will resign as a member in the company’s supervisory board to take up his new role.